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Abstract Nonalcoholic liver disease is a global public health problem that increases 
cardiovascular morbidity and mortality in these patients. This paper discusses endothelial 
dysfunction among patients (adolescents and young adults) with nonalcoholic liver 
disease.  
On the one hand, evidence suggests that cardiovascular disease is the leading cause of 
mortality in patients with advanced nonalcoholic liver disease and that nonalcoholic fatty 
liver is associated with an increased risk of cardiovascular disease independent of the 
presence of cardiovascular risk factors and metabolic syndrome components.  
On the other hand, nonalcoholic liver disease, especially the non-inflammatory form 
of nonalcoholic steatohepatitis, may not only be a marker of cardiovascular damage but 
also a factor involved in its pathogenesis. Such patients are candidates not only for the 
treatment of liver disease but also for the early treatment of cardiovascular risk factors 
because many of them, especially those with severe nonalcoholic liver disease, will 
develop major cardiovascular events and may eventually die of cardiovascular disease 
before the advanced liver disease occurs. 
Keywords  nonalcoholic liver disease, cardiovascular disease, endothelial dysfunction, intima-media 
thickness 
Highlights  Nonalcoholic fatty liver disease is commonly associated with obesity, type-2 diabetes, 
hypertension and dyslipidemia. 
 These patients are candidates not only for the treatment of liver disease, but also for the 
early treatment of cardiovascular risk factors. 
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Introduction 
Nonalcoholic fatty liver disease (NAFLD) is a 
pathological condition with an increasing incidence, being 
a major cause of morbidity and mortality in both adults 
and children (1). Over the past 30 years, the interest in 
studying NAFLD has increased progressively, with the 
condition being partly already known, but certainly 
underestimated, especially among adolescents. With the 
increasing prevalence of obesity and diabetes among the 
general population, non-alcoholic fatty liver disease has 
become an important public health issue (1). In Europe, in 
well-developed countries, it is estimated that 20-30% of 
adults and 3-10% of children are affected by NAFLD (2). 
The latest data estimate that 6 million people in the 
United States suffer from nonalcoholic steatohepatitis 
(NASH), about 600,000 individuals developed NASH 
post-cirrhosis, and 13-14% of children have NAFLD (3). 
Moreover, the World Health Organization (WHO) warns 
that underdeveloped and developing countries will 
experience in the next 10 to 20 years the "double burden" 
of the co-existence of undernutrition and obesity in the 
same population, thus favoring the emergence of NAFLD 
(4). Children exposed to malnutrition are more susceptible 
to the harmful effects of "cheap" diets (which are 
hyperlipidic, hyperglucidic, rich in sodium, hypercaloric 
and nutrient-rich), thus favoring fat accumulation at the 
visceral level (5). 
 NAFLD includes a wide range of liver disorders, 
from simple steatosis to steatohepatitis, associated with 
necro-inflammation and/ or fibrosis. The disease, in its 
more severe forms, can lead to cirrhosis, for which the 
only existing therapeutic strategy is liver transplantation 
(6). The effects of specific risk factors such as obesity and 
a sedentary lifestyle associated with genetic 
predispositions lead to the development of NAFLD in 
children (7). However, despite the high prevalence and 
the increased morbidity, the pathogenesis and the 
consequences of this condition have not yet been fully 
elucidated. 
Discussions 
Nonalcoholic fatty liver disease is commonly 
associated with obesity, type-2 diabetes, hypertension, 
and dyslipidemia, most patients presenting central obesity 
and evidence of insulin resistance (1, 8). These 
associations support the idea that this disorder may be the 
hepatic expression of the metabolic syndrome. The 
relationship between nonalcoholic liver disease and 
metabolic syndrome has suggested a possible role for 
nonalcoholic liver disease in the pathogenesis of 
cardiovascular disease. In addition, there have been 
studies showing that patients with nonalcoholic liver 
disease have an increased prevalence and incidence of 
cardiovascular diseases (9, 10). At the same time, it is not 
surprising that cardiovascular diseases are the leading 
cause of death in patients with nonalcoholic liver disease, 
being responsible for about 30% of all deaths (11, 12). 
Instead, only a few of the NAFLD patients develop 
cirrhosis or die due to liver disease complications. 
Although cardiovascular disease is the leading cause of 
death in NAFLD patients, it is less clear whether NAFLD 
increases morbidity and mortality independently of the 
presence of traditional cardiovascular risk factors (13, 
14). In the literature, some studies have shown that the 
magnitude of the association between NAFLD and 
cardiovascular disease is diminished after adjusting for 
metabolic factors (15), although several studies suggest 
that NAFLD remains an independent risk factor for 
cardiovascular disease (14, 16). 
 Since the prevalence of NAFLD in adolescents and 
young adults has reached alarming levels, it is important 
to determine whether liver disease independently 
increases the risk of cardiovascular disease in these 
individuals. It is well known that atherosclerosis begins at 
birth, the reason young individuals with NAFLD may 
have a potentially increased cardiovascular risk from 
early ages (16, 17). 
 Although an association between nonalcoholic liver 
disease and atherosclerotic risk factors has been described 
in adult patients, possible relationships between them in 
youngsters still remain to be elucidated. The pathological 
findings of a study based on the association between fatty 
liver and atherosclerosis, performed on 817 pediatric 
patients who died from external causes (accident, 
suicide), showed that fatty liver was present in 15% of 
them, mild atherosclerosis in 21%, and moderate to severe 
atherosclerosis in 2%. Atherosclerosis was significantly 
more frequent (p < 0.0001) in patients with fatty liver 
(30%) than in those without fatty liver (19%) (18). 
 Studies that used carotid ultrasound to measure the 
intima-media thickness showed that it was increased in 
children with family hypercholesterolemia, diabetes 
mellitus, hypertension, and obesity (18, 19). 
 Obesity in children and adolescents is a predictive 
factor for a wide range of conditions that occur later on, 
and obesity likely increases the risk of cardiovascular 
morbidity and mortality, functional and morphological 
changes of the vascular wall being found in obese 
youngsters (20). A prospective study published in 2001, 
performed on children and youngsters suffering from 
Endothelial dysfunction and nonalcoholic liver disease 
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morbid obesity, reported the presence of endothelial 
dysfunction and an increase in arterial wall resistance 
though without significant thickening of the intima-media 
thickness (20). However, more recent studies have 
compared obese children with non-obese ones and have 
shown a significant increase in the intima-media thickness 
in obese patients (21, 22). At the same time, the reduction 
of the intima-media thickness measured at the carotid 
level in obese subjects after exercise and diet suggests a 
certain degree of reversibility of early changes in 
atherosclerosis (23-25). 
 The biological mechanisms by which nonalcoholic 
liver disease contributes to the acceleration of 
atherosclerosis, independent of other risk factors, have not 
yet been thoroughly understood. Many studies have 
shown that insulin resistance plays an essential role in the 
occurrence of cardiovascular clinical events in patients 
with nonalcoholic liver disease (26-28). There has been 
an association between insulin resistance and the intima-
media thickness at the carotid level (29), but hepatic 
steatosis may be atherogenic despite the association with 
insulin resistance. The concentration of adiponectin, 
acytokine with antiatherogenic properties, may be another 
basic mechanism that links nonalcoholic liver disease 
with atherosclerosis (30, 31). Prospective studies have 
shown a connection between low adiponectin levels and 
cardiovascular disease. Patients with nonalcoholic liver 
disease also have a significant decrease in the adiponectin 
level, and this decrease is associated with the histological 
severity of liver disease, independent of abdominal 
obesity and other components of the metabolic syndrome 
(31). 
  Studies have investigated the interaction between 
adiponectin, nonalcoholic liver disease, and 
atherosclerosis by using the pulse wave velocity measured 
in the ankle and arm (32, 33), but a statistically significant 
correlation between the adiponectin values and the 
velocity of the pulse wave did not occur. Thus, other 
atherogenic mechanisms may be involved in patients with 
nonalcoholic liver disease, including oxidative stress and 
subclinical inflammation (18). 
 Obese subjects, as well as patients with nonalcoholic 
liver disease, frequently have elevated levels of 
inflammatory markers, atherosclerosis being 
systematically associated with inflammation (18). Studies 
have, for example, shown an increased level of interferon-
secreting T-CD4-positive cells in obese children, a pro-
inflammatory factor (34) which lowers collagen 
production and activates macrophages, effects that favor 
the breakdown of the atheromatous plaque. Additional 
studies are required to evaluate the role of pro-
inflammatory cytokines and their interposition between 
hepatic disease and systemic atherosclerosis in children 
and adolescents. 
 In recent years, a theory has been proposed to explain 
the development of fatty liver in obese children and 
adolescents, called the "two-stroke theory" (35). 
Hepatosteatosis and hyperlipidemia cause the first stroke, 
respectively resistance to insulin, followed by the second 
stroke of cytokine release and oxidative stress producing 
inflammation, fibrosis and cirrhosis in the liver (35-37). 
 The first signs of atherosclerosis are fat streaks which 
appear in childhood; recent studies identified the presence 
of fat streaks in fetuses of mothers who suffer from 
hypercholesterolemia (38). The progression of fat streaks 
is accelerated by hyperlipidemia, smoking, arterial 
hypertension, obesity, and diabetes. Early detection and 
elimination of risk factors slow down the progression and 
even the regression of the lesions (39, 40). In recent years, 
the interest in the early detection of atherosclerotic lesions 
that can lead to asymptomatic lethality has increased (32). 
Nowadays, the development of imaging studies leads to 
the observation of the early vascular changes by using 
non-invasive ultrasonography (40). These early changes 
include the thickening of the arterial wall, arterial 
stiffness, and impaired vasodilator function (32). 
 Studies have revealed an increase in hepatosteatosis 
with increasing body mass index (BMI) and abdominal 
obesity in children. An Italian study on 75 obese children 
reported an important association between the degree of 
hepatosteatosis determined by ultrasonography, the body 
mass index, and the level of transaminases (41). 
Hepatosteatosis is accompanied by an inflammatory 
process; the increase of the transaminases is common 
after the occurrence of steatohepatitis (42-45). Therefore, 
screening by using liver enzymes may not be sufficient in 
order to detect liver disease in obese patients, and 
therefore other diagnostic methods should be used. 
Conclusions 
Nonalcoholic liver disease is a global public health 
problem that takes into account the increasing 
cardiovascular morbidity and mortality in these patients. 
So far, evidence suggests that cardiovascular diseases are 
the leading cause of mortality in patients with advanced 
nonalcoholic liver disease and that nonalcoholic fatty 
liver is associated with an increased risk of cardiovascular 
disease independent of the presence of cardiovascular risk 
factors and metabolic syndrome components. Although 
additional research is needed to draw a final conclusion, 
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there is still the possibility that nonalcoholic liver disease, 
especially the non-inflammatory form of nonalcoholic 
steatohepatitis, may not only be a marker of 
cardiovascular damage but also a factor involved in its 
pathogenesis. This process can occur through the 
systematic release of proatherogenic factors from the fatty 
liver or through its contribution to insulin resistance and 
atherogenic dyslipidemia. 
These patients are candidates not only for the 
treatment of liver disease but also for the early treatment 
of cardiovascular risk factors, because many of them, 
especially those with severe nonalcoholic liver disease, 
will develop major cardiovascular events and will 
eventually die of cardiovascular disease before the 
advanced liver disease occurs. 
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